52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.

Autor:	Melgosa Ramos FJ; Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain. Electronic address: javimelgo@gmail.com., Mateu Puchades A; Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain., Matáix-Díaz J; Department of Dermatology, Hospital Marina Alta, Vila-Joyosa, Alicante, Spain., Schneller-Pavelescu L; Department of Dermatology, Hospital de la Vega Baja, Orihuela, Alicante, Spain., Belinchón-Romero I; Department of Dermatology, General University Hospital of Alicante, Alicante, Spain., Santos Alarcón S; Department of Dermatology, University Hospital Virgen de los Lirios, Alcoy, Alicante, Spain.
Jazyk:	English; Spanish; Castilian
Zdroj:	Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2024 Jul-Aug; Vol. 115 (7), pp. 722-726. Date of Electronic Publication: 2024 Mar 29.
DOI:	10.1016/j.ad.2023.08.019
Abstrakt:	Tildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the Spanish routine clinical practice setting. This was a retrospective multicenter study that included a total of 91 psoriatic patients on tildrakizumab. The mean Psoriasis Area and Severity Index (PASI) was 9.09 (SD, 5.30). The overall tildrakizumab survival rate was 93.47% for a mean treatment exposure of 30.18 weeks (SD, 16.57). No drug discontinuation was associated with drug tolerability, or adverse reactions. Absolute PASI ≤3 was reached by 91.3% and 96.5% of the patients on weeks 28 and 52, respectively. Response was not impacted by weight, age (>65), metabolic syndrome, presence of arthritis, or previous number of biological therapies used. Based on our own experience tildrakizumab is an effective strategy to treat plaque psoriasis and difficult-to-treat-areas. (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu